Electronic Batch Records: Replacing Paper in GMP Manufacturing

Walk any legacy plant floor and you will find it. The binder. Three inches thick, tabbed and initialed, a paper batch record that took an operator a full shift to fill in and will take a reviewer the better part of a week to read. Somewhere inside is a figure crossed out, re-initialed, re-dated, then crossed out again. Somewhere is a signature certifying that a person was, at some moment, physically present with a pen. It is a lovely artifact of a certain era. In 2026, it is also out of step.

For most of the industry’s modern life, paper was simply how regulated manufacturing dressed itself. It looked serious. It felt accountable. A signed page carried the weight of a promise. But taste changes, and so do standards, and the paper record now reveals what it always was beneath the ceremony: slow, fragile, and quietly expensive. The most modern thing a facility can do today is retire it, and move to an electronic batch record running on a system validated to stand up in front of an inspector.

The true cost of paper is not paper

The cost of a paper-based system is rarely the paper. It is what the paper permits. Handwriting that cannot be read. Fields left blank because a shift ended. A calculation done in a margin and transcribed one digit wrong. Each of these is small on its own. In aggregate, they are the difference between a batch released on time and a batch held for investigation.

Regulators have been unusually clear about this. Documentation practices, the polite name for data integrity, account for roughly a fifth of drug GMP warning letters. A full enumeration of 1,766 FDA warning letters issued between 2016 and 2023 mapped their data integrity violations against the ALCOA and ALCOA+ frameworks, and a separate 15-year analysis traced the arc: data integrity moved from negligible before 2014 to roughly a quarter of violations by 2016, even as the annual volume of warning letters climbed from around 17 to more than 300. Enforcement is not softening.

The operational cost is just as real. In its analysis of pharmaceutical quality operations, McKinsey found that digitization and automation reduce manual errors and variability, with early Industry 4.0 use cases cutting deviations by more than 65 percent and closing the ones that remain more than 90 percent faster. This is not a story about clumsy operators. It is a story about a medium that asks people to be flawless with a pen, then penalizes the entirely human moments when they are not.

Here is the same argument without the prose, for anyone who skims:

There is a dignity argument too, and readers of any industry understand it. A facility that still runs on paper is asking its best people to spend their attention on legibility instead of judgment. It is the professional equivalent of a couture house cutting cloth with kitchen scissors. The work may still be excellent. It simply is not being given the tools it deserves.

The new silhouette of the plant floor

What replaces paper is not a single product but a posture. The industry has a name for it now: Pharma 4.0, a term trademarked by the International Society for Pharmaceutical Engineering to describe the fourth industrial revolution as it lands in a heavily regulated world. It is not, ISPE is careful to say, a piece of software you buy. It is an operating model built across four dimensions: resources, information systems, organization and processes, and culture. Its animating idea is data integrity by design, the notion that trustworthy records should be a property of the system itself rather than a discipline imposed on tired humans at the end of a shift.

The look of a Pharma 4.0 floor is deceptively plain. There is less on the workbench. The clipboard is a tablet. The logbook is a screen that greets the operator with exactly the step they are on and refuses to let them skip the one before it. Underneath that calm surface, a great deal is in motion. Scales report weights directly. Historians such as the PI System and enterprise systems such as SAP exchange status in real time. Equipment declares its own identity and pulls forward every record ever associated with it. The silos that made one plant feel like an island begin to dissolve, and information that once lived in a filing cabinet becomes something a director in another time zone can see the moment it is captured.

The shift is not one system. It is the whole paper estate, converted record by record, and each piece is its own category of validated software:

• Electronic logbooks for equipment usage, cleaning, calibration, and maintenance, with real-time asset status and standardization across plants.
• Electronic batch records (eBR) that enforce the activity sequence, capture entries with validation checks, and release by exception.
• Forms and checklists for SOP checks, deviations, CAPA, training records, cleaning verification, and EHS assessments, configurable with little or no custom code.
• Weigh and dispense with live scale integration, potency calculations, excipient adjustments, weigh-booth cleaning enforcement, and enforced recipe adherence.
• Manual data entry to historians that writes operator readings straight to PI tags or asset framework attributes, with asset-based upper and lower limits.

Each of these retires a stack of clipboards. Together they retire the estate.

ISPE puts the stakes plainly for anyone still weighing it. Pharma 4.0, its maturity work argues, is less an obligation than a competitive advantage, and its absence is increasingly a business risk. That is the quiet verdict of the season. The connected floor is not the daring choice anymore. It is the expected one.

Why precision is a must

If there is a single feature that explains why the electronic batch record is not merely faster but better, it is review by exception. The idea is elegant. Instead of a reviewer reading every line of a completed record in search of a rare error, the system screens each entry against the master batch record as it is captured and surfaces only what falls outside specification. ISPE describes it as an approach in which manufacturing and quality data are screened so that only critical exceptions reach an approver for disposition.

The upside is not hypothetical. McKinsey’s work on pharmaceutical quality control found that early Industry 4.0 use cases delivered:

• 30 to 40 percent gains in productivity, even in already efficient labs.
• More than 50 percent reductions in overall quality-control costs.
• More than 65 percent fewer deviations, with over 90 percent faster closure.

Looking wider, McKinsey’s view of the future of biopharma manufacturing holds that product transfer times could fall from months to days, and the costs of poor quality could be all but eliminated.

Review by exception institutionalizes right-first-time execution. As one EY analysis of electronic batch records notes, the method shifts attention onto exception trends, so corrective action lands where deviations actually originate, while stripping away the cognitive load of manual calculation and transcription. The reviewer stops proofreading and starts thinking. That is not a cost saving. It is a promotion.

Off the shelf, or Custom eBR?

Once you accept that paper is finished, a second question arrives, and it is the one the platform vendors would rather you skipped. Not whether to go digital, but whose digital, and how much of your operation you will reshape to fit it. Off-the-shelf batch-execution platforms sell speed. What they rarely say out loud is the trade: to move fast, you re-engineer your process to fit their software. For a greenfield line with generic unit operations, that can be acceptable. For an established site with validated processes, legacy L2 automation, a historian, a LIMS, and an ERP already in production, “reconfigure your operation around our product” is an expensive sentence.

It helps to name the field. The market is led by a handful of mature platforms, and any manufacturer weighing this decision will already have them on the shortlist:

• Körber PAS-X (formerly Werum PAS-X) — The de facto standard for electronic batch records in regulated pharma and biologics, with a mature eBR module built around GAMP 5, 21 CFR Part 11, and Annex 11. Its no-code configuration engine adapts quickly to different processes, but you are configuring within Körber’s process model, and the validated capability is licensed, not owned.
• Siemens Opcenter Execution Pharma (formerly SIMATIC IT eBR) — A heavyweight MES that treats the batch record as one module among many. It offers the deepest fit for sites already standardised on Siemens PLC and DCS automation, at the cost of long deployment cycles and specialist consultants.
• Rockwell Automation FactoryTalk PharmaSuite — A pharma-specific MES delivering electronic batch records, recipe management, and real-time production monitoring, strongest where the plant is already built on Rockwell control hardware.
• POMSnet Aquila (POMS) — A fully web-based life-sciences MES covering recipe, materials, and equipment management alongside electronic batch records, positioned as a lighter, faster-to-deploy option than the enterprise suites.
• CaliberBRM (Caliber) — A purpose-built EBR focused specifically on eliminating paper batch manufacturing records and enforcing data integrity, rather than a full manufacturing execution system.

Every one of these is a capable, compliant product. The point is not that any is poorly made. It is that they are ready-to-wear: the pattern is already cut, and you are the one altered to fit it. The alternative is made to measure, a validated, configurable solution fitted to the process you already run, rather than a process rebuilt around someone else’s software. Fit the software to the validated process, not the reverse.

The signature that finally means something

For all its romance, the wet-ink signature was always a weak form of proof. It gave you a name. It did not tell you when, in what order, whether anything changed afterward, or whether the person signing held the authority to. The electronic signature, governed by FDA 21 CFR Part 11 in the United States and EU Annex 11 in Europe, tells you all of it, and it does so without asking anyone to carry a page from one building to another.

Behind every compliant electronic entry sits an audit trail, which is really just a system’s memory: who did what, when, and what state the record was in before and after. Data integrity here is spelled out by the ALCOA and ALCOA+ principles, that records be attributable, legible, contemporaneous, original, and accurate, with the plus adding complete, consistent, enduring, and available. On paper, ALCOA+ is an aspiration you audit toward. In a well-built electronic batch record system it is enforced at the moment of capture, which is a very different and far calmer way to work.

There is a security dividend as well. Configurable sign-offs let time-sensitive approvals happen across regions in parallel rather than in sequence. Biometric authorization adds a layer a shared password never could. And when an auditor arrives, the answer to their hardest question, show me the full history of this record, becomes a matter of seconds rather than an afternoon in the archive.

What a electronic batch record system gives you

Validated is the word that separates a spreadsheet from a system an auditor will accept. A validated electronic batch record system, and the wider GxP software around it, arrives documented, qualified, and compliant, and the strongest ones are configurable rather than bespoke, which is precisely why they go live in months rather than years. The validation package is not a tax on the project. It is the asset you are buying.

What a well-chosen, validated eBR and digital records platform puts on the floor:

• Review by exception out of the box, so QA reviews only what is flagged.
• Right-first-time execution through guided, sequence-enforced workflows.
• Integration with ERP such as SAP, historians such as the PI System, and your IIoT layer, so data is captured once and never re-keyed.
• Barcode, QR, and biometric entry to cut both effort and error.
• Configurable security groups and enforced field completion.
• Mobile-first access on tablet, phone, or browser, on premises or in the cloud.
• 21 CFR Part 11 and EU Annex 11 compliance, with a complete, time-stamped audit trail.

Configurable matters as much as validated. A solution that maps onto the processes you already run, rather than forcing you to reshape the plant around the software, is one your power users can extend themselves. New department, new log, new form: internal teams expand the system without a vendor on site for every change.

Start with one record, then scale

The smart move is not to boil the ocean. It is to pick the record that hurts most, validate it, prove the hours saved, and let the result make the case for the next one.

There is a lighter footprint in it, too. A single organization can generate hundreds of thousands of controlled paper records across a product lifecycle, each one printed, moved, stored, and eventually destroyed. Removing them is not only cheaper and safer. It is measurably greener, which is increasingly its own line on the scorecard.

The only question left is how soon

Paper enjoyed a long and dignified run in pharmaceutical manufacturing. It served an industry that had nothing better. That is no longer the situation. The tools now exist to make records that are legible by default, trustworthy by design, and reviewable in hours.

The paperless floor is not the avant-garde choice. It is the well-dressed one. If your floor still runs on paper, the next step is not a rip-and-replace. It is a short, honest conversation about which record fails you most often, and a validated, configurable solution, a logbook, an electronic batch record, a set of forms, a weigh-and-dispense workflow, mapped to how you already work. The only real question this season is not whether to leave paper behind, but how soon, and how gracefully.

For the full playbook, BGO’s Ultimate GMP Validated System Guide walks through validation, workflow design, and automation step by step.

Dobrin Kolarov

Healthcare business analyst with expertise in marketing and business development, and holds an MPharm degree. He specialises in creating and executing communication strategies that make digital health solutions and pharmaceutical technologies clear, accessible, and resonation for their audiences.

link to the author’s linkedin profile